Arovella Therapeutics Ltd (Arovella), based in Australia and the US, is a world leader in reformulating and delivering medication through the oral mucosa.
Patients typically take medication as pills, tablets or capsules yet less than 25% of the medication is absorbed into the bloodstream.
Arovella can increase the bioavailability of administered medications, which means it increases the amount of the drug absorbed by the body so is able to increase the effect of that drug.
Arovella has increased bioavailability up to 95%. This is a major step forward in the evolution of drug delivery technology.
Company News /
by Adrian Tan -
5 months ago
25 Oct 2024 - Arovella Therapeutics (ASX:ALA) has recently released its quarterly report, announcing the receipt of a $3.0 million Research and Development (R&D) Tax Incentive refu…
Market Reports /
by Peter Milios -
A year ago
17 Apr 2023 - At the closing bell, the S&P/ASX 200 was 0.27 per cent higher at 7,381.50, led by gains in the financials and real estate sectors.
Market Reports /
by Peter Milios -
A year ago
17 Apr 2023 - Nine out of the eleven sectors are trading higher today. Information technology is surging on the back of gains from WiseTech Global (ASX:WTC), Xero (ASX:XRO), and Al…
Market Reports /
by Peter Milios -
2 years ago
10 Feb 2023 - UBS Chief Economist George Tharenou has revised his peak cash rate forecast to 3.85 per cent in mid-2023, up from a previous forecast of 3.35 per cent in mid-February…
Market Reports /
by Peter Milios -
2 years ago
10 Feb 2023 - The Reserve Bank of Australia has revised its inflation forecasts, stating that the rapidly rising prices in the country have probably peaked. The central bank upgrad…
Market Reports /
by Peter Milios -
2 years ago
31 Jan 2023 - Australian shares fluctuated on Tuesday with a 0.4 per cent gain and later 0.2 per cent loss. Consumer stocks led the gains, up 2.3 per cent, while tech stocks weighe…
Market Reports /
by Peter Milios -
2 years ago
31 Jan 2023 - Retail sales in Australia fell 3.9% in December, surprising expectations for a 0.2% decline. The ABS Head of Retail Statistics noted that the fall follows 11 consecut…
Interviews /
by Lauren Hayes -
2 years ago
15 Nov 2022 - Arovella Therapeutics Limited (ASX:ALA) Managing Director and CEO Dr Michael Baker provides an update on the company.
Market Reports /
by Peter Milios -
2 years ago
07 Nov 2022 - Materials is the strongest sector by far in today’s trading. This was due to the initial possibility that China would begin to ease COVID restrictions. As such, BHP (…
Market Reports /
by Lauren Hayes -
2 years ago
07 Nov 2022 - US markets finished higher on Friday after a volatile session following the release of the October jobs report, which showed better-than-expected hiring, while the un…
Market Reports /
by Peter Milios -
2 years ago
31 Oct 2022 - All eyes are on tomorrow's expected interest rate hike, with many predicting a 50 basis point rise. At the closing bell, the S&P/ASX 200 was 1.15 per cent or 77.80 po…
Market Reports /
by Lauren Hayes -
2 years ago
31 Oct 2022 - The local market has commenced the week in the green with the S&P/ASX 200 up 0.94 per cent or 63.70 points higher to 6,849.40 at noon. This comes off the back of US e…
Market Reports /
by Peter Milios -
2 years ago
26 Oct 2022 - CPI data from the September quarter has sharply exceeded estimates. As such, multiple banks have made predictions for the next rate rise.
Market Reports /
by Lauren Hayes -
2 years ago
26 Oct 2022 - The S&P/ASX 200 posted gains this morning as sentiment from Wall Street overnight improved over the Fed potentially turning less aggressive, combined with a decline i…
Interviews /
by Tim McGowen -
2 years ago
29 Sep 2022 - Arovella Therapeutics Limited (ASX:ALA) Managing Director and CEO Michael Baker discusses the company's collaboration with Imugene to combine therapies.
Market Reports /
by Paul Sanger -
2 years ago
26 Sep 2022 - Australian shares have started the week sharply lower after global equity markets tumbled on Friday. Concerns over global growth and a strengthening US dollar combine…
Interviews /
by Lauren Evans -
3 years ago
22 Nov 2021 - Arovella Therapeutics Limited (ASX:ALA) CEO & Managing Director Dr Michael Baker provides an update on the company's invariant Natural Killer T (iNKT) cell platform a…
Company Presentations /
by -
3 years ago
18 Nov 2021 - Arovella Therapeutics Limited (ASX:ALA) Managing Director and CEO Dr Michael Baker provides an update on the company's recently acquired licence from Imperial College…
Company News /
by Lauren Evans -
3 years ago
03 Sep 2021 - Suda Pharmaceuticals (ASX: SUD) has appointed Dr John Maher to its scientific advisory board for the iNKT cell therapy platform.
Interviews /
by Lauren Evans -
3 years ago
01 Jul 2021 - SUDA Pharmaceuticals Limited (ASX:SUD) CEO & Managing Director Dr Michael Baker discusses the company's acquisition of the invariant natural killer T (iNKT) cell ther…
Company Presentations /
by -
4 years ago
24 Nov 2020 - SUDA Pharmaceuticals Limited (ASX:SUD) Managing Director and CEO Dr Michael Baker provides an overview of the company, discussing its OroMist technology, Zolpimist an…
